Monday, 27 April 2020

Global Pericarditis Market to Quadruple by 2023; Foretells MRFR

Market Synopsis of Global Pericarditis Market:
Global Pericarditis Market analysis by Type (Acute Pericarditis, Recurrent Pericarditis and Chronic Pericarditis), Diagnosis & Treatment [Diagnosis (Electrocardiogram (ECG), Echocardiogram, Computerized Tomography (CT) and X-Ray) and Treatment (Medication (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Colchicine) and Surgical Treatment), End User (Hospitals & Clinics and Medical Institutes & Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2023
Market Scenario:
Pericarditis is inflammation of the pericardium (the fibrous sac surrounding the heart). Symptoms typically include a sudden onset of sharp chest pain. The pain may also be felt in the shoulders, neck, or back. It generally is better sitting up and worse when lying down or breathing deeply.
The increasing prevalence of cardiovascular diseases such as heart attack & hypertension, favorable reimbursement policies, and increasing preference for minimally invasive procedures are the major drivers propelling market growth. However, the side-effects of anti-inflammatory drugs and the risk of bacterial infections constrain the growth of the market.
The Global Pericarditis Market is expected to register 7.96% CAGR and is anticipated to reach USD 2,741.39 Million by 2023.
Market Dynamics
The prevalence of cardiovascular diseases is found to be increasing over the last decade. This is attributed to the rising incidences of chronic diseases such as obesity and diabetes, which are major risk factors for cardiovascular diseases such as pericarditis, heart attack, and hypertension. As per the American Heart Association, nearly 92.1 million Americans were diagnosed with cardiovascular diseases in 2017. Additionally, it also stated that the prevalence is found to be higher in men than in women. Furthermore, in the same year, more than 92% of the patients exhibited major symptoms of heart diseases such as chest pain, heartburns, and strokes.
Recently, the prevalence of cardiovascular diseases is found to be increasing from the last few years. The American Heart Association stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the people had hypertension.
Cardiovascular disease is one of the significant chronic disease responsible for a high death toll across the globe. This emphasizes the need for the development of new diagnostics and treatment devices around the world. The market is also affected by the increasing number of people diagnosed with these diseases at an early stage. Therefore, the prevalence of cardiovascular disease would drive the growth of the market during the forecast period.
The market is driven by the increasing number of patients suffering from cardiovascular diseases, thus signifying the need for the development of new technologically advanced devices for monitoring the heart rate. Continuous monitoring of cardiovascular diseases is an important aspect of cardiology. Therefore, the prevalence of pericarditis is increasing with a rise in the prevalence of cardiovascular diseases, fueling market growth.
Segmentation
The global pericarditis market has been segmented into type, application, and end user. 
Based on type, the global market has been segmented acute pericarditis, recurrent pericarditis, and chronic pericarditis.
Based on diagnosis & treatment, the global market has been divided into diagnosis and treatment. The diagnosis segment is further divided into electrocardiogram (ECG), echocardiogram, computerized tomography (CT), X-Ray. The treatment segment is bifurcated into medication (non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine) and surgical treatment.
Based on end user, the global market has been segmented into hospitals & clinics and medical institutes & research laboratories. The hospitals & clinics segment accounted for a market value of USD 840.30 million in 2017.
Key Players
The prominent players in the global pericarditis market are Pfizer Inc., AstraZeneca Plc, Novartis International AG, Allergan plc., and Merck & Co., Inc. are the top five market players in this market. Apart from these, Bayer AG, Reckitt Benckiser Group Plc., PerkinElmer, Inc., FUJIFILM Holdings Corporation, Sanofi, and Johnson & Johnson Services, Inc. are some of the other major players in the global market.
Some of the key strategies followed by the players operating in the global pericarditis market are innovation, product development, acquisition, and expansion.
Regional Analysis
The global pericarditis market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is estimated to dominate the global pericarditis market during the forecast period. This is attributed to the rising investments in research and development owing to investments in reputed research centers and government institutions and increasing expenditure on healthcare play a vital role in the growth of the regional market. Besides, several research grants are given by governmental agencies.
The European market for pericarditis is expected to be the second-largest during the forecast period. The presence of medical device companies, the rising burden of rheumatoid arthritis (RA), and growing healthcare spending are expected to boost the growth of the market in this region. Additionally, the companies operating in the market are mainly focusing on mergers and acquisition, which is expected to support market growth.
Asia-Pacific is estimated to be the fastest-growing market due to the growing geriatric population, rapid developments in technology. In addition to this, improving healthcare infrastructure has increased the number of research activities in the region. Moreover, in the region, China accounted for a market share of 24.6% in 2017.
Furthermore, the market in the Middle East & Africa is expected to witness slow growth due to limited access to healthcare facilities.
Key Updates
  • In July 2017, Pfizer Inc. extended the collaboration with Catalent, Inc., a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products for the development and manufacture of Advil Liqui-Gels.
  • In October 2018, Reckitt Benckiser (RB) launched a 24-hour pain relief patch along with a campaign to educate patients about pain to encourage patients to facilitate pain management.
  • In October 2018, FUJIFILM Medical Systems USA, Inc., a provider of diagnostic imaging and medical informatics solutions launched the FCT Embrace wide bore computed tomography (CT) imaging unit in the US, thereby entering into the US computed tomography market.
Posted by at No comments:

Microbiology Testing Market Size, Share 2020 Global Analysis By Trends, Growth, Statistics, Region And Industry Forecast To 2023

Global Microbiology Testing Market - Overview
Microbiology testing has emerged as one of the rapidly changing and growing segment of healthcare over the past few years. Microbiology testing deals with the study of microbial germs and their clinical applications for the improvement of health. Microbiology testing is concern with the diagnosis, prevention and treatment of various infectious diseases such as, sexually respiratory infections, urinary tract infections, gastrointestinal infections, sexually transmitted infections, and many others. These diseases can be spread from one person to another, directly or indirectly.
According to a recent study published by the Market Research Future analysts, the global microbiology testing market is growing at a double digit growth rate; mainly due to factors such as technological advancements, rising cases of infectious diseases, surveillance programs for disease control, and rising stringency of standards.  On the other hand, erroneous results produced during the testing, and heavy costs of the tests and instruments have created some obstacles in the growth of this market in all parts of the world.
Global Microbiology Testing Market - Competitive Analysis
There are large number of companies involved in the development of the products, instruments, and test kits for the microbiology testing which are now being used in majority part of the developed countries. Global microbiology testing market is majorly dominated by Biomérieux SA with more than 40% of market share in 2016.
Major companies are adopting a specific strategy to enter and create unique space in this market. The different strategies includes, product launch, agreement and collaboration, partnership and expansion, joint venture and strategic alliance etc. All major players are focusing on new product development to provide new and innovative solutions to the market.
Biomérieux SA offers a comprehensive range diagnostic solutions which include Microbiology lab instruments, reagents and software. The products of the company is mainly used for diagnosing infectious diseases. In 2016, BioMérieux announced the acquisition of Hyglos. With this acquisition, the company plans to strengthen its position in the market.
Some of the major developments in this segment came from the Roche Diagnostics. In April 2017, the company received FDA clearance for the CINtec Histology test. This test is the only clinically validated p16 biomarker test. The CINtec Histology test will help physicians make informed decisions as to the best course of care for patients with high-grade pre-cancerous cervical disease. Back in 2015, Roche acquired GeneWEAVE to strengthen offerings in microbiology diagnostics.
The global market consist of players such as Alere (US), BD (US), Beckman Coulter, Inc. (US), Biomérieux SA (France), Cepheid (US), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (US). These are the prominent players at the forefront of competition in the global microbiology testing market and are profiled in MRFR Analysis report.
Global Microbiology Testing Market - Regional Analysis
In 2016, North America and Europe were holding more than half market share of global microbiology testing market. Increasing funding for R&D is major driving force for the market growth. The funding for microbiology testing in US is one of the highest as compared to other countries. Rapid adoption of advanced products and techniques are driving the growth for North America market. Increasing cases of infectious diseases are promoting the research related activities in this region. Independent laboratories are dominating the North America market by adopting new technologies and trends.
European market is second highest revenue generator after North America. Europe microbiology testing market has benefited by the presence of some major players in this region. Moreover, increasing innovation and changing laboratory practices are driving the growth for Europe microbiology testing market. Microbiology testing have huge and increasing demand not only in developed countries but also in developing countries like China, India, and Spain.
Rising prevalence of respiratory infections are increasing burden on Asia-Pacific healthcare system. Being a large population base, increasing aging population, and increasing use of technology in healthcare, China microbiology testing market is growing at rapid pace. China is expected to grow at a CAGR of 12.8% during the forecast period. The number of independent laboratories are rapidly increasing such as KingMed Diagnostics and Dian Diagnostics. KingMed Diagnostics is largest chain of independent laboratories in china.
The Middle East and Africa microbiology testing market is growing dramatically due increasing prevalence of various infectious diseases like Ebola. This region is carrying greatest burden of infectious disease. Sexually transmitted diseases are also major public health problem in this region. There are some factors are affecting the microbiology testing market in this region such as, limited access to the healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, limited availability of products etc.
Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microbiology-testing-market-697 

Posted by at No comments:

Pathological Microscopes Market Comprehensive Overview, Industry Size, Booming Share, Key Players Review, Phenomenal Growth and Business Boosting Strategies till 2023

Market Scenario
The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.
The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.
The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market size over the next few years.
Competitive Analysis
Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).
The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.
Segmentation
The pathological microscopes market is segmented by type, application, and end-user.
By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.
By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.
By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.
Regional Analysis
The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.
Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.
Industry News:
In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.
In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.
Posted by at No comments:

Telehealth Market Statistics 2020 by Key Driving Factor, Dazzling Growth, Vital Players, Regions, Segments, Diagnosis, Treatment & End-User Outlook to 2024

The Global Telehealth Market share is expected to register a CAGR of 22.74% during the forecast period with a market value of USD 16,173.8 Million till 2025. Telehealth connects patients to fundamental health care services through remote monitoring, video conferencing, electronic consultations, and wireless communications. The increasing occurrences of chronic diseases along with rising elderly population are projected to drive the market growth. However, privacy and security concerns, as well as a lack of awareness about telehealth, is likely to hamper the growth of the market during the assessment period.
Segment Analysis
The global telehealth market has been segmented into a mode of delivery, component, application, and end user.
The global telehealth market, by mode of delivery, has been divided into web/cloud-based and on-premise. The web/cloud-based segment held a large share due to the wide preferability, whereas the on-premise segment is projected to be the fastest-growing due to the increasing awareness among healthcare professionals.
The global telehealth market, by component, has been bifurcated into services, software, and hardware. The services segment accounted for the largest share owing to the increasing developments by key companies, whereas the software segment is expected to be the fastest-growing due to the increasing preference towards the usage of telehealth software. The market, by hardware, has been sub-segmented into monitoring devices, medical peripherals, and others. The market, by monitoring devices, has been further divided into stationary and wearable monitoring devices. The market, by medical peripherals, has been segregated into blood pressure monitors, ECG monitors, pulse oximeters, blood glucose meters, peak flow meters, otoscopes, and others. The market, by software, has been further sub-segmented into integrated software and standalone software. The market, by services, has been further classified as remote monitoring, real-time interactions, and store-and-forward consultations.
The global telehealth market, by application, has been classified as radiology, cardiology, primary care, neurophysiology, and others. The radiology segment held a major share due to the increased use of telehealth expertise in the radiology field, whereas the cardiology segment is likely to be the fastest growing owing to the increased prevalence rates of cardiac diseases.
The global telehealth market, by the end user, has been categorized as hospitals and clinics, diagnostic clinics, home care, and others. Hospitals and clinics segment held a major share due to the increase in the number of hospitals, whereas the diagnostic clinics segment is expected to be the fastest-growing segment due to the increased usage of telehealth services.
Market Player
MRFR recognizes the following companies as the key players in the global telehealth market— Boston Scientific Corporation (US), GlobalMed (US), Maple (Canada), Siemens (Germany), Cisco Systems Inc. (US), AMD Global Telemedicine Inc. (US), Allscripts Healthcare Solutions (US), Care Innovations LLC (US), Right Health (Canada), Honeywell International Inc. (US), American Well (US),  InTouch Technologies Inc. (US), Philips Healthcare (Netherlands), Medtronic plc (Ireland), Dialogue (Canada), Livecare Health (Canada)and Cerner Corporation (US).
Regional Analysis
The global telehealth market, based on region, has been analyzed across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is projected to dominate the global telehealth market. This can be attributed to the increasing adoption of telehealth services. Also, the increased number of initiatives taken by various organizations in the US is also likely to help the growth of the market. For instance, in 2016, Kaiser Permanente, a care consortium based in California, conducted more consultations virtually than in person, i.e., nearly 52% of 110 million physician visits were via online portals, virtual visits, or apps.
The Europe market for telehealth is anticipated to be the second-largest market. The shift towards more organized and continuous diagnosis and treatment monitoring is expected to be an important factor for the growth of the market.
Asia-Pacific is assessed to be the fastest-growing region in the global market due to the rise in the elderly population, an increase in incidence rates of chronic diseases, and the lack of technical personnel.
The Middle East & Africa are expected to witness stable growth due to inadequate access and healthcare affordability among the healthcare firms in this region.
Key Findings of the Study
  • The Global Telehealth Market is estimated to grow at USD 16,173.8 million by 2025 at a CAGR of 22.74% during the assessment period
  • Americas accounted for the largest share of the global market due to the presence of key market players in the US and Canada
  • Based on component, the services segment accounted for the largest market share of 93% in 2018
  • Based on mode of delivery, the web/cloud-based segment accounted for the largest market share of 6% in 2018
  • On the basis of application, the radiology segment accounted for the largest market share of 32.6% in 2018
  • On the basis of end user, the hospitals and clinics segment accounted for the largest market share of 39.4% in 2018
Posted by at No comments:

Cough Syrup Market Growth Opportunities, Analysis and Forecasts Report 2020-2024

Market Highlights
The Global Cough Syrup Market Share is estimated to be valued at USD 5,139.63 Million by 2026 and is projected to register a CAGR of 3.45% during the forecast period.
Cough syrups are a medication used for the temporary relief of coughs, sneezing, or runny noses due to the common cold, hay fever, or other upper respiratory allergies.
The increasing incidence of respiratory disorders along with the rising air pollution are some of the key trends contributing to the growth of the cough syrup market. Additionally, the growing geriatric population, along with the strong pharmaceutical sector, is boosting market growth as aged people are more prone to respiratory disorders. Furthermore, the market is expected to witness lucrative growth due to increasing product developments.
However, product recalls, and the stringent regulatory scenario are hampering the growth of the market.
Segment Analysis
The global cough syrup market has been segmented into product type, category, and application. Based on product type, the market has been segregated into combination and individuals. Combination product type has been further sub-segmented into dextromethorphan + guaifenesin, guaifenesin + pseudoephedrine, brompheniramine + pseudoephedrine. The individual product type has been further divided into dextromethorphan, guaifenesin, ambroxol, and codeine. Based on the category, it has been classified as cough suppressants and expectorants. Based on application, the cough syrup market has been categorized as adults and children.
Market Players
Market Research Future (MRFR) recognizes Pfizer, Inc. (US), Novartis AG (Switzerland), Merck KGaA (US), Johnson & Johnson Services, Inc. (US), GlaxoSmithKline PLC (UK), Acella Pharmaceuticals, LLC (US), Procter & Gamble (US), Reckitt Benckiser Group PLC (UK), Abbott (US), and Sanofi (France) as the key players in the global cough syrup market.
Regional Analysis
The global cough syrup market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to hold a maximum share of the global cough syrup market, and the regional market is projected to register a CAGR of 3.16% during the forecast period. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region.
Europe accounts for the second-largest, in the global cough syrup market, majorly due to the presence of key players such as Novartis, GlaxoSmithKline, and Reckitt Benckiser Group PLC. The cough syrup market in Europe is expected to be driven by the growth of the pharmaceutical industry in Germany, France, and the UK.
Asia-Pacific is estimated to be the fastest-growing market due to the continuous development in developing countries such as India and China. High prevalence of respiratory diseases due to tobacco smoke, exposure to air pollutants at home and the workplace, vehicular pollution, and indoor air pollution from biological agents related to damp and mold further increase the risk of respiratory disease in children and adults in these countries.
The Middle East & Africa cough syrup market has been segmented into major two regions, the Middle East and Africa. The developed countries in the region, such as the UAE and Saudi Arabia, are the ones with the maximum share of the cough syrup market. The advancing healthcare infrastructure, increasing healthcare expenditure, and increasing per capita disposable income of the people in these countries are some reasons leading to the large share of the market in these countries. Africa is the least developed region with limited healthcare resources and facilities for the people. The low growth rate due to less developed and less efficient health systems is hampering the growth of the market.
Key Findings of the Study:
  • The global cough syrup market was valued at USD 3,920.87 million in 2018, is estimated to grow at USD 5,139.63 million by 2026 at a CAGR of 3.45% during the assessment period.
  • The Americas is expected to hold a maximum share of the global cough syrup market. The presence of significant market players in the region, strategic acquisitions by major players to enhance product portfolio, increasing cases of respiratory disorders, and availability of advanced medications for the treatment of chronic obstructive pulmonary disease (COPD) is expected to drive the market growth in this region.
  • Based on the category, the cough suppressants segment accounted for the largest market share of 61% in 2018.
  • Based on application, the children segment dominated the market and projected to register the highest CAGR of 78% during the forecast period.

Posted by at No comments:

Medical Smart Textile Market significant CAGR to be Achieved by Worldwide Major Vendors, Recent Trends and Forecast till 2027

Market Insights:
The Global Medical Smart Textile Market is expected to register a CAGR of 7.51% to reach 2,105.32 Million by 2027. Medical smart textile is a new field of research and is most widely used in the healthcare sector. Sensors are integrated into the textiles, in continuous contact with the human body, and could capture physiological changes occurring within the body. The demand for medical smart textiles is increasing due to the rising burden of diseases, evolving methods of diagnosis, and extensive use of wearable medical devices. These factors are expected to fuel the growth of the global medical smart textile market. However, the high cost of smart textiles is anticipated to hamper the market growth.
Key Players
The global medical smart textile market overview by Market research Future contains The top prominent players like Schoeller Switzerland, Vista Medical Ltd, Sensoria Inc., Gentherm, Siren, Pireta, AiQ Smart Clothing, Camira Fabrics, Carre Technologies Inc, and 3teks.
Some of the key strategies followed by players operating in the global medical smart textile market were innovation, product development, and acquisition & mergers.
  • In February 2019, Gentherm signed a partnership agreement with ThermoAnalytics, Inc., a leading thermal modeling software development firm for the advancement of human thermal comfort predictions.
  • In June 2019, Pireta developed a unique process that adds conductive metallic pattern directly into textile clothing without changing the fabric feel. These wearable smart garments and e-textile enabled physicians to diagnose diseases in their early stages and provide better treatment options. The launch of this device would help the company to increase its revenue in the future.
  • In July 2019, Camira Fabric acquired Luna Textiles, a US-based company that manufactures fabric for healthcare, hospitality, and other lounge seating purposes. This acquisition helped Camira Fabric to increase its revenue.
Market Dynamics
The rising burden of diseases is expected to fuel the growth of the global medical smart textile market during the forecast period. According to the Global Burden of Disease Study in 2017, from 1990 to 2017, the leading causes of premature deaths were neonatal disorders, ischemic heart disease, lower respiratory infections, diarrhea, chronic obstructive pulmonary disease (COPD), and strokes. These diseases accounted for more than 1 million deaths worldwide in 2017. Additionally, the Global Burden of Disease Study in 2017, stated that there was a change in the mortality rate due to excess drug-resistant tuberculosis from 2007 to 2017.
Segmentation
The global medical smart textile market has been segmented by technology, application, and end user. The market, based on technology, has been divided into wearable technology, textile sensors, and others. Based on application, the medical smart textile market has been segregated into bio-monitoring, surgery, therapy, and wellness and others. The global medical smart textile market, based on end user, has been bifurcated into hospitals and clinics and others. The hospitals and clinics held a share of 67.3% in 2018.
Regional Market Summary
The global medical smart textile market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to dominate the global medical smart textile market. The growth in this region can be attributed to the extensive use of medical devices. Moreover, applications in medical engineering for monitoring vital health indicators help in maximizing the growth of the market in this region. Europe held a substantial share in the global medical smart textile market. This can be attributed to the rising government expenditure to promote the healthcare sector in the region. For instance, according to Eurostat, in 2016, healthcare expenditure per person was EUR 5,000 or higher in three EU member states that are Luxembourg (EUR 5,600), Sweden (EUR 5,100) and Denmark (EUR 5,000), as the per-person healthcare expenditure is very high in Europe and is continuously growing. Asia-Pacific is estimated to be the fastest-growing region in the global market. This is due to the extensive demand for advanced medical devices and increasing applications of technology in the early diagnosis of diseases fueling the growth of the medical smart textile market in the region. The medical smart textile market in the Middle East & Africa is expected to witness a modest market growth rate from 2019 to 2027. The Middle East would lead the market growth in this region. Increasing awareness about medical smart textiles is expected to drive market growth during the assessment period.
Posted by at No comments:

Implantable Cardioverter Defibrillator (ICD) Market Size, Share 2020 Global Analysis By Trends, Growth, Statistics, Region And Industry Forecast To 2025

Market Synopsis
The Global Implantable Cardioverter Defibrillator (ICD) Market: Increasing prevalence of cardiovascular diseases, growing aging population, and changing lifestyles are projected to boost the Implantable Cardioverter Defibrillator (ICD) Market Size from USD 6,952.2 Million in 2018 to 10,425.96 Million by 2025 at a CAGR of 5.96%.
Top Key Players
Top Implantable Cardioverter Defibrillator (ICD) Market Manufacturers in the Global market are Abbott Laboratories (US), BIOTRONIK (Germany), Boston Scientific Corporation (US), Medtronic (Ireland), MicroPort Scientific Corporation (China), Koninklijke Philips N.V. (Netherlands), Nihon Kohden Corporation (Japan), Progetti Srl (Italy), Fukuda Denshi Co., Ltd (Japan), Getinge (Sweden), ZOLL Medical Corporation (US), etc.
Market Highlights
According to MRFR analysis, the global implantable cardioverter defibrillator (ICD) market is expected to register a CAGR of 5.96% during the forecast period of 2019 to 2025. Implantable Cardioverter Defibrillator (ICD) is used to record the heart's activity and treat dangerous ventricular arrhythmias with an electrical shock or pulse to the heart. Factors such as the growing aging population, changing lifestyles such as smoking and alcohol consumption, and the increase in demand for cardiac implants are responsible for the increasing prevalence of cardiac arrhythmias globally. This is likely to fuel the growth of the ICD market during the forecast period. In addition to this, improving efficacy of ICDs for the treatment of cardiac diseases over a period will also fuel the market. According to the American Heart Association, approximately 1.5 million cases of myocardial infarction occur annually, and the incidence rate is approximately 600 cases per 100,000 people in the US. According to the American College of Cardiology Foundation, sudden cardiac arrest (SCA) is also one of the leading causes of death worldwide and is responsible for 250,000 to 450,000 deaths per year in the US. Also, coronary artery disease is a major risk factor for sudden cardiac arrest (SCA).
The global implantable cardioverter defibrillator (ICD) market is currently dominated by numerous market players. The key players are involved in new product launches and strategic collaborations to strengthen their market positions. For instance, in May 2019, the US Food and Drug Administration (FDA) has approved Boston Scientific's Emblem S-ICD that is used in the treatment of cardiovascular diseases. Through this approval, Boston Scientific focuses on strengthening its position in the US ICD market. Medtronic is developing Extravascular (EV) ICD system, an innovative subcutaneous ICD that is designed to terminate arrhythmias, post-shock pacing to protect from sudden cardiac arrest, and temporary back-up bradycardia pacing.
Segmentation
By Type
  • Regular ICD: Holdsthe highest share in the market due to the increasing occurrences and growing incidence rates of autoimmune diseases.
  • Cardiac Resynchronization Therapy Defibrillators (CRT-D): Holds the second-largest share in the market and is expected to grow at a moderate rate during the forecast period. The growth is mainly due to increasing cardiac arrests among patients, R&D by major players, and strategic partnerships
  • Subcutaneous-ICD (S-ICD): Holds the third-largest share in the market and is expected to grow at a steady rate in the market during the forecast period. New product launches, manufacturing facility expansion in emerging countries such as India, China, Brazil, and other emerging countries could drive the market.
  • Others: Covers accessories and small component parts of implantable cardioverter defibrillators. This segment holds the least share in the market.
By Indication
  • Myocardial Ischemia: Myocardial Ischemia is the largest as well as the fastest-growing segment by indication as ICDs are majorly used in the treatment of myocardial ischemia. Moreover, the prevalence rate of sudden cardiac arrests is rising. Myocardial ischemia is further segmented into symptomatic and asymptomatic.
  • Acute Myocardial Infarction: It is the second-largest segment in the market, and this condition is also commonly called a heart attack. Acute myocardial infarction is a life-threatening condition that occurs when blood flow to the heart muscle is abruptly cut off, causing tissue damage. It is the second-largest segment in the market by indication.
  • Electrolyte Imbalance and Drug Toxicity: It is the third-largest and fastest-growing segment in the market.
By End User
  • Hospitals & Clinics: This is the largest and fastest-growing market segment and is projected to grow well beyond the forecast period. Hospitals and clinics are primary care centers for individuals afflicted with type-1 diabetes and are also cost-effective. Moreover, in countries with government-funded healthcare and a high prevalence of type-1 diabetes, hospitals and clinics are the main treatment centers, which drives the growth of the segment.
  • Ambulatory Surgical Centers: A more specialized treatment option, a large number of specialty centers have established across the US and are being opened in developing nations such as India and China. This segment is growing due to the increased number of individuals afflicted with the condition and the higher returns on investment from specialty centers as compared to hospitals and clinics.
  • Others: The ease of availability and delivery of diabetes medication has led to patients opting for home treatment. The segment also covers old age homes as the geriatric population is highly susceptible to type-1 diabetes. The segment is expected to grow as awareness regarding the condition increases along with the ease of treatment.
Regional Analysis
The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The ICD market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The ICDs market in the Americas is likely to hold a major share owing to the increased patient pool. The European ICD market has been sub-divided classified as Western Europe and Eastern Europe. The Western European market has further been classified categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The ICD market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific ICD market is projected to be the fastest-growing due to the increasing incidences of acute myocardial infarction and myocardial infraction, growing aging population, and changing lifestyle (smoking and alcohol consumption) in the region. The ICD market in the Middle East & Africa has been divided into the Middle East and Africa.
Posted by at No comments:
Subscribe to: Comments (Atom)